Cantor Fitzgerald analyst Alethia Young started Verastem Oncology with an Overweight rating and $5 price target. The launch of the company's first drug, Copiktra, is in the early days and investor expectations remain very low for commercial potential, Young tells investors in a research note. The analyst sees an opportunity for Copiktra, due to unmet need in the 20,000 relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma patients. The market underappreciates the commercial potential for Copiktra, says the analyst.